Equities research analysts expect Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) to announce per share of $0.18 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Sensus Healthcare’s earnings, with the lowest EPS estimate coming in at $0.15 and the highest estimate coming in at $0.21. Sensus Healthcare posted of ($0.02) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 1,000%. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Sensus Healthcare will report full-year earnings of $1.53 per share for the current financial year, with EPS estimates ranging from $1.32 to $1.74. For the next year, analysts anticipate that the company will report earnings of $0.93 per share, with EPS estimates ranging from $0.55 to $1.30. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that provide coverage for Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.06 by $0.91. Sensus Healthcare had a return on equity of 38.23% and a net margin of 62.07%. During the same quarter last year, the firm earned ($0.07) earnings per share.
SRTS has been the topic of a number of research analyst reports. TheStreet raised Sensus Healthcare from a “c” rating to a “b-” rating in a report on Friday, February 11th. Zacks Investment Research raised Sensus Healthcare from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Thursday. HC Wainwright raised their target price on Sensus Healthcare from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Thursday, March 3rd. Finally, Maxim Group restated a “buy” rating and issued a $14.00 target price on shares of Sensus Healthcare in a research report on Friday, May 6th.
In other Sensus Healthcare news, CFO Javier Rampolla sold 9,000 shares of the business’s stock in a transaction dated Friday, March 4th. The stock was sold at an average price of $9.42, for a total value of $84,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Nicolas Soro sold 10,000 shares of the business’s stock in a transaction dated Wednesday, March 9th. The stock was sold at an average price of $10.20, for a total value of $102,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,056 shares of company stock valued at $1,227,218. 24.30% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dorsey Wright & Associates acquired a new position in shares of Sensus Healthcare in the 1st quarter worth approximately $54,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Sensus Healthcare by 83.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. Now owns 5,500 shares of the company’s stock worth $40,000 after buying an additional 2,500 shares in the last quarter. HCR Wealth Advisors acquired a new position in Sensus Healthcare during the 4th quarter worth $72,000. AE Wealth Management LLC acquired a new position in Sensus Healthcare during the 1st quarter worth $192,000. Finally, Goldman Sachs Group Inc. acquired a new position in Sensus Healthcare during the 4th quarter worth $141,000. 20.49% of the stock is currently owned by institutional investors.
SRTS stock Opened at $8.97 on Thursday. Sensus Healthcare has a 1 year low of $3.08 and a 1 year high of $11.96. The firm has a market cap of $149.62 million, a P/E ratio of 7.01 and a beta of 0.52. The stock has a 50-day simple moving average of $9.22 and a 200-day simple moving average of $8.06.
About Sensus Healthcare (Get Rating)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids ; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sensus Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.